{"entity":{"id":"nct05462613","kind":"trial","name":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","aka":["REPROGRAM-02"],"tldr":"A phase 2/3 trial of regorafenib, aspirin and bevacizumab (glioblastoma use) in colorectal cancer, run by Centre Hospitalier Universitaire de Besancon, now recruiting.","summary":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer is a phase 2/3, randomised interventional study registered as NCT05462613 by Centre Hospitalier Universitaire de Besancon, with a registry enrolment figure of 446 participants, started 2023-05-09 and due to reach its primary completion in 2029-11. Interventions recorded: quality of life questionnaires; Blood sample; Regorafenib; Metronomic chemotherapies; Aspirin; Bevacizumab; FOLFIRI or FOLFOX. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: best objective response during treatment period (phase II); overall survival (OS) (phase III). Colorectal eligibility wording from the registry: \"Patients with histologically proven metastatic colorectal cancer in progression after a first line of chemotherapy +/- targeted therapy\". Sites: France. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05462613","url":"https://clinicaltrials.gov/study/NCT05462613"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["regorafenib","aspirin","bevacizumab-glioma"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05462613","phase":"2/3","setting":"Induction Regorafenib in Combination With Metronomic Cyclophosphamide, Capecitabine, and Low-dose Aspirin Followed by Chemotherapy in Second Line Metastatic Colorectal Cancer Carcinoma An Open-label Randomized Phase II-III Study","sponsor":"Centre Hospitalier Universitaire de Besancon","enrolled":446,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05462613/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"aspirin","kind":"drug","name":"Aspirin","route":"/drugs/aspirin/"},{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"regorafenib","kind":"drug","name":"Regorafenib","route":"/drugs/regorafenib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}